成都康弘药业集团股份有限公司 关于2021年股票期权激励计划部分股票期权 注销完成的公告

Group 1 - The company announced the cancellation of 524,300 stock options from the 2021 stock option incentive plan due to certain incentive targets not being fully met by some participants [1][2] - The cancellation affects 31 incentive participants and is in accordance with the relevant regulations of the "Management Measures for Equity Incentives of Listed Companies" [2] - The cancellation will not significantly impact the company's financial status or operational results, nor will it affect the motivation and stability of the management team [2] Group 2 - The company has submitted the application for the cancellation of the stock options to the Shenzhen branch of China Securities Depository and Clearing Corporation Limited, which has been confirmed and completed [2] - The board of directors assures that the information disclosed is true, accurate, and complete, with no false records or misleading statements [1]